Spongy degeneration of the central nervous system
Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC
| Spongy degeneration of the central nervous system | |
|---|---|
| File:U fibres big.JPG | |
| Synonyms | Canavan disease, ASPA deficiency |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Developmental delay, hypotonia, macrocephaly, seizures |
| Complications | N/A |
| Onset | Infancy |
| Duration | Lifelong |
| Types | N/A |
| Causes | Genetic mutation in the ASPA gene |
| Risks | Ashkenazi Jewish descent |
| Diagnosis | Genetic testing, MRI |
| Differential diagnosis | Leigh syndrome, Alexander disease |
| Prevention | N/A |
| Treatment | Supportive care, physical therapy, occupational therapy |
| Medication | N/A |
| Prognosis | Poor, progressive neurological decline |
| Frequency | Rare |
| Deaths | N/A |
Spongy degeneration of the central nervous system is a rare genetic disorder characterized by the degeneration of the central nervous system (CNS) leading to the formation of spongy tissue. This condition is also known as Canavan disease, named after the researcher who first described it. It primarily affects infants and young children, leading to severe neurological impairment.
Pathophysiology[edit]
The disease is caused by mutations in the ASPA gene, which encodes the enzyme aspartoacylase. This enzyme is responsible for breaking down N-acetylaspartic acid (NAA) in the brain. In the absence of functional aspartoacylase, NAA accumulates, leading to the formation of spongy tissue in the brain's white matter. The accumulation of NAA disrupts the normal development and maintenance of myelin, the protective sheath surrounding nerve fibers. This disruption results in the characteristic spongy degeneration seen in affected individuals.
Clinical Features[edit]
Symptoms of spongy degeneration of the CNS typically appear in early infancy. Affected infants may exhibit poor muscle tone (hypotonia), developmental delays, and an enlarged head (macrocephaly). As the disease progresses, children may experience seizures, feeding difficulties, and loss of previously acquired skills.
Diagnosis[edit]
Diagnosis is often based on clinical presentation and confirmed through genetic testing for mutations in the ASPA gene. Magnetic resonance imaging (MRI) of the brain can reveal the characteristic spongy degeneration and white matter changes.
Prenatal diagnosis is possible through amniocentesis or chorionic villus sampling if there is a known family history of the disease.
Treatment[edit]
Currently, there is no cure for spongy degeneration of the CNS. Treatment is supportive and focuses on managing symptoms and improving quality of life. This may include physical therapy, nutritional support, and medications to control seizures.
Research into potential treatments, such as gene therapy, is ongoing. Gene therapy aims to deliver a functional copy of the ASPA gene to affected cells, potentially correcting the underlying enzyme deficiency.
Prognosis[edit]
The prognosis for individuals with spongy degeneration of the CNS is generally poor. Most affected children do not survive beyond early childhood, although the severity and progression of the disease can vary.
